logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Manufacturers
    3. Actelion Pharmaceuticals US, Inc.

    Actelion Pharmaceuticals US, Inc. drugs

    FiltersReset Filters
    6 results

    • opsumit

      (macitentan)
      Actelion Pharmaceuticals US, Inc.
      Usage: OPSUMIT is indicated for treating pulmonary arterial hypertension (PAH, WHO Group I) to reduce disease progression and hospitalization risks. Its effectiveness was demonstrated in a long-term study involving patients with various forms of PAH, primarily those with WHO Functional Class II–III symptoms.

    • opsynvi - macitentan and tadalafil tablet, film coated

      (Macitentan And Tadalafil)
      Actelion Pharmaceuticals Us, Inc.

    • tracleer

      (bosentan)
      Actelion Pharmaceuticals US, Inc.
      Usage: TRACLEER is indicated for treating pulmonary arterial hypertension (PAH) in adults and pediatric patients (3 years and older) to improve exercise ability and reduce clinical worsening. It is effective for idiopathic, heritable, and PAH associated with connective tissue or congenital heart diseases.

    • uptravi

      (Selexipag)
      Actelion Pharmaceuticals US, Inc.
      Usage: UPTRAVI is indicated for treating pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce hospitalization risk. Its efficacy was demonstrated in a long-term study involving patients with WHO Functional Class II–III PAH symptoms, including idiopathic, heritable, and connective tissue disease-related PAH.

    • veletri

      (epoprostenol)
      Actelion Pharmaceuticals US, Inc.
      Usage: VELETRI is indicated for treating pulmonary arterial hypertension (PAH) (WHO Group 1) to enhance exercise capacity, primarily in patients with NYHA Functional Class III–IV symptoms, including idiopathic or heritable PAH and PAH linked to connective tissue diseases.

    • zavesca

      (miglustat)
      Actelion Pharmaceuticals US, Inc.
      Usage: ZAVESCA is indicated as monotherapy for treating adult patients with mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not suitable, such as in cases of allergy, hypersensitivity, or poor venous access.